HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US COVID-19 Fraud: FTC Points To Peptides As Latest Scam, Silver Remedy Firm Shut Down

Executive Summary

FTC warns 20 firms selling products or services promising to prevent or treat COVID-19, including three clinics saying peptides help boost the effectiveness of a vaccine. NJ business promoting collodial silver to prevent or treat novel coronavirus infection shut down in a DoJ complaint after failing to comply with regulatory agencies' warning.

You may also be interested in...



Pfizer And BioNTech Claim COVID-19 Vaccine Success

The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.

Criminal Charges, Warnings Continue Climbing In US COVID-19 Consumer Health Fraud Enforcement

FDA counts 102 warning letters covering more than 1,000 products in its coronavirus fraud oversight while FTC’s  total had reached 332. Latest criminal charges are against operator of a Georgia business following FDA investigation of OTC sales of a misbranded drug called “Immune Shot” falsely advertised to lower consumer’s risk of contracting COVID-19 by nearly 50%.

Drug Claims For CBD, Detoxification Supplements Make Warning List Along With Pandemic Fraud

Latest warning letters published by FDA include not only two more about claims for supplements to prevent or treat the disease caused by the novel coronavirus, but also warnings about good manufacturing practices violations and noncompliant claims for CBD-containing products and for a detoxification line.

Related Content

Topics

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel